Related Experiment Videos
Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes
Martin G Larson1, Larry D Atwood, Emelia J Benjamin
1The National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA. mlarson@bu.edu
Insights
This genome-wide study identified potential genetic variants linked to cardiovascular diseases (CVD), including coronary heart disease (CHD), atrial fibrillation (AF), and heart failure (HF). Findings highlight chromosome 9p21 associations, suggesting new avenues for CVD prevention.
Area of Science:
- Genetics
- Cardiology
- Population Health
Background:
- Cardiovascular diseases (CVD), encompassing coronary heart disease (CHD), stroke, heart failure (HF), and atrial fibrillation (AF), are leading causes of mortality globally.
- Genetic predisposition plays a significant role in the development of various CVD manifestations.
- Previous research has identified single gene variants associated with specific CVD outcomes.
Purpose of the Study:
- To conduct a community-based genome-wide association study (GWAS) to identify genetic variants associated with major cardiovascular disease outcomes.
- To analyze associations between single nucleotide polymorphisms (SNPs) and major atherosclerotic CVD, major CHD, AF, and HF.
Main Methods:
- Utilized data from 1345 Framingham Heart Study participants across 310 pedigrees.
- Analyzed 70,987 qualifying SNPs using the Affymetrix 100K GeneChip.
- Employed proportional hazards models and generalized estimating equations to test SNP-trait associations in additive genetic models.
Main Results:
- Identified six significant associations with p-values less than 10(-5) for major CVD, major CHD, AF, and HF.
- Confirmed associations of a 13 Kb region on chromosome 9p21 with major CVD and major CHD, consistent with prior GWAS findings.
- Found associations of rs10501920 in CNTN5 with both AF and HF.
Conclusions:
- While no single association reached genome-wide significance, several intriguing genetic associations with CVD were identified.
- Replicated previously reported associations between chromosome 9p21 and major CVD.
- Further studies are warranted to validate these findings and explore novel CVD pathways and potential targeted preventive therapies.
Background:
Cardiovascular disease (CVD) and its most common manifestations--including coronary heart disease (CHD), stroke, heart failure (HF), and atrial fibrillation (AF)--are major causes of morbidity and mortality. In many industrialized countries, cardiovascular disease (CVD) claims more lives each year than any other disease. Heart disease and stroke are the first and third leading causes of death in the United States. Prior investigations have reported several single gene variants associated with CHD, stroke, HF, and AF. We report a community-based genome-wide association study of major CVD outcomes.
Methods:
In 1345 Framingham Heart Study participants from the largest 310 pedigrees (54% women, mean age 33 years at entry), we analyzed associations of 70,987 qualifying SNPs (Affymetrix 100K GeneChip) to four major CVD outcomes: major atherosclerotic CVD (n = 142; myocardial infarction, stroke, CHD death), major CHD (n = 118; myocardial infarction, CHD death), AF (n = 151), and HF (n = 73). Participants free of the condition at entry were included in proportional hazards models. We analyzed model-based deviance residuals using generalized estimating equations to test associations between SNP genotypes and traits in additive genetic models restricted to autosomal SNPs with minor allele frequency > or =0.10, genotype call rate > or =0.80, and Hardy-Weinberg equilibrium p-value > or = 0.001.
Results:
Six associations yielded p < 10(-5). The lowest p-values for each CVD trait were as follows: major CVD, rs499818, p = 6.6 x 10(-6); major CHD, rs2549513, p = 9.7 x 10(-6); AF, rs958546, p = 4.8 x 10(-6); HF: rs740363, p = 8.8 x 10(-6). Of note, we found associations of a 13 Kb region on chromosome 9p21 with major CVD (p 1.7-1.9 x 10(-5)) and major CHD (p 2.5-3.5 x 10(-4)) that confirm associations with CHD in two recently reported genome-wide association studies. Also, rs10501920 in CNTN5 was associated with AF (p = 9.4 x 10(-6)) and HF (p = 1.2 x 10(-4)). Complete results for these phenotypes can be found at the dbgap website http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007 webcite.
Conclusion:
No association attained genome-wide significance, but several intriguing findings emerged. Notably, we replicated associations of chromosome 9p21 with major CVD. Additional studies are needed to validate these results. Finding genetic variants associated with CVD may point to novel disease pathways and identify potential targeted preventive therapies.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenomics: Identification of New Drug Targets
Imaging Studies for Cardiovascular System V: CT
Acute Coronary Syndrome III: Diagnostic Studies